- Trials with a EudraCT protocol (274)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
274 result(s) found for: Cancer of Unknown Primary.
Displaying page 1 of 14.
EudraCT Number: 2018-004562-33 | Sponsor Protocol Number: CheCUP | Start Date*: 2019-12-04 | |||||||||||
Sponsor Name:University Heidelberg, Med. Fac. repr. by University Hospital and its Commercial Managing Director | |||||||||||||
Full Title: A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or ... | |||||||||||||
Medical condition: Cancer of unknown primary site (CUP-Syndrome), relapsed/refractory to platinum-based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005865-67 | Sponsor Protocol Number: PXD101-CLN17 | Start Date*: 2008-12-11 | |||||||||||
Sponsor Name:Topotarget A/S | |||||||||||||
Full Title: An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated c... | |||||||||||||
Medical condition: Patients with previously untreated carcinoma of unknown primary | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001661-32 | Sponsor Protocol Number: VeTo | Start Date*: 2012-07-05 | |||||||||||||||||||||
Sponsor Name:Vejle Hospital, Dept. of Oncology | |||||||||||||||||||||||
Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status | |||||||||||||||||||||||
Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003174-18 | Sponsor Protocol Number: PACET-CUP | Start Date*: 2009-12-18 |
Sponsor Name:Universitätsklinikum Heidelberg | ||
Full Title: Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated ... | ||
Medical condition: adeno- and undifferentiated Carcinoma of Unknown Primary (CUP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005481-18 | Sponsor Protocol Number: BNT142-01 | Start Date*: 2022-04-28 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:BioNTech SE | ||||||||||||||||||||||||||||||||||||||
Full Title: First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced sol... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Claudin 6 (CLDN6)-positive advanced solid tumors | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003040-20 | Sponsor Protocol Number: MX39795 | Start Date*: 2018-06-20 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemoth... | |||||||||||||
Medical condition: Cancer of Unknown Primary Site | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing) EE (Completed) IE (Completed) DE (Temporarily Halted) CZ (Ongoing) FI (Ongoing) LV (Completed) HU (Ongoing) PL (Completed) FR (Ongoing) ES (Ongoing) BG (Ongoing) PT (Ongoing) HR (Ongoing) NL (Ongoing) DK (Completed) CY (Prematurely Ended) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001912-38 | Sponsor Protocol Number: ACR-CMOD / 2005-2 | Start Date*: 2006-01-11 |
Sponsor Name:ACROSS | ||
Full Title: PHASE II TRIAL OF THE COMBINATION OF GEMCITABINE AND OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY SITE Estudio fase II de la combinación de gemcitabina... | ||
Medical condition: METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY SITE | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005018-47 | Sponsor Protocol Number: 008-IRCC-10IIS-14 | Start Date*: 2015-04-08 | |||||||||||
Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, MULTICENTER STUDY TO ASSESS THE EFFICACY OF NAB-PACLITAXEL-BASED DOUBLET AS FIRST LINE THERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY (CUP): the AGNOSTOS trial | |||||||||||||
Medical condition: Cancers of Unknown Primary (CUP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004247-23 | Sponsor Protocol Number: LUMC201811 | Start Date*: 2019-03-22 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: [89Zr]trastuzumab PET/CT imaging of HER2 positive breast cancer for predicting pathologic complete response after neoadjuvant chemotherapy; A multicentre study | ||
Medical condition: HER2+ breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003522-86 | Sponsor Protocol Number: P18.210 | Start Date*: 2019-03-21 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Imaging tumor angiogenesis using 18F-Fluciclatide PET/CT in patients with colorectal and pancreatic cancer. | ||
Medical condition: Patient suffering from colorectal or pancreatic adenocarcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004163-12 | Sponsor Protocol Number: RP2017-001 | Start Date*: 2018-01-28 | |||||||||||
Sponsor Name:ReposPharma | |||||||||||||
Full Title: A phase 2a TDM-guided clinical study on the safety and efficacy of mebendazole in patients with advanced gastrointestinal cancer or cancer of unknown origin | |||||||||||||
Medical condition: Squamous cell cancer or adenocarcinoma, including primary cancer of the liver, of the gastrointestinal tract or cancer of unknown origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003707-18 | Sponsor Protocol Number: Evelien05 | Start Date*: 2014-04-22 | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: Absorption of sublingual delivered fentanyl (Abstral®) in head and neck cancer patients treated with curatively aimed chemo-radiotherapy | |||||||||||||
Medical condition: head and neck cancer patients treated with chemo-radiotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004323-20 | Sponsor Protocol Number: BNT211-01 | Start Date*: 2020-06-30 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:BioNTech Cell & Gene Therapies GmbH | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) NL (Ongoing) SE (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001207-42 | Sponsor Protocol Number: CONFERMER | Start Date*: 2014-06-03 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI PARMA | ||||||||||||||||||
Full Title: Multicenter randomized trial comparing erlotinib vs mono-chemotherapy in the third-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown | ||||||||||||||||||
Medical condition: Third-line treatment in patients with non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004321-83 | Sponsor Protocol Number: GEFCAPI04 | Start Date*: 2014-01-27 |
Sponsor Name:Institut Català d'Oncologia (ICO) | ||
Full Title: A randomised phase III trial comparing a strategy based on molecular analysis to the empiric strategy in patients with carcinoma of an unknoun primary (CUP) | ||
Medical condition: Carcinomas of an unknown primary site (CUP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019821-32 | Sponsor Protocol Number: 20090508 | Start Date*: 2010-11-04 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fa... | |||||||||||||
Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) PT (Completed) CZ (Prematurely Ended) SI (Completed) GR (Completed) SE (Completed) LV (Completed) EE (Completed) IT (Completed) BG (Completed) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017946-30 | Sponsor Protocol Number: 20060517 | Start Date*: 2011-01-19 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Prim... | |||||||||||||
Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) SK (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed) DK (Completed) DE (Completed) PL (Completed) GR (Completed) LV (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000206-18 | Sponsor Protocol Number: PM1183-B-005-14-QT | Start Date*: 2015-09-10 | |||||||||||
Sponsor Name:PharmaMar S.A., Sociedad Unipersonal | |||||||||||||
Full Title: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients with Selected Solid Tumors | |||||||||||||
Medical condition: - small cell lung cancer (SCLC) - head and neck carcinoma (H&N) - neuroendocrine tumors (NETs) - biliary tract carcinoma - endometrial carcinoma - BRCA 1/2-associated metastatic breast carcinoma - ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022902-41 | Sponsor Protocol Number: BIG4-11/BO25126/TOC4939g | Start Date*: 2011-09-26 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in pa... | |||||||||||||
Medical condition: Patients with operable HER2-positive primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Ongoing) CZ (Completed) ES (Ongoing) FR (Ongoing) IE (Ongoing) SE (Ongoing) DK (Completed) SI (Ongoing) NL (Ongoing) BE (Ongoing) SK (Completed) AT (Trial now transitioned) IT (Ongoing) BG (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001641-40 | Sponsor Protocol Number: ESR-17-12933 | Start Date*: 2019-09-09 | ||||||||||||||||
Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | ||||||||||||||||||
Full Title: Induction Durvalumab (MEDI4736) & Radiotherapy (RT) for Locally Advanced but Resectable Head and Neck Squamous Cell Carcinomas: A Pilot Study | ||||||||||||||||||
Medical condition: Advanced resectable head and neck tumor | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.